Inflammatory biomarkers in late-life depression: a systematic review and meta-analysis of interleukin-1β, interleukin-6, tumor necrosis factor-α, and C-reactive protein.
Key claim: A meta-analysis of 18 observational studies shows that peripheral inflammatory biomarkers—including IL-1β, IL-6, TNF-α, and CRP—are significantly elevated in older adults with late-life depression compared to healthy controls.
Abstract
Late-life depression (LLD)-encompassing both major depressive disorder and clinically significant depressive symptoms-affects approximately 1-5% of adults aged 60 and older when defined by strict diagnostic criteria, while clinically significant depressive symptoms affect 8-16% of community-dwelling older adults. Antidepressant treatment in older adults is challenging due to smaller effect sizes, higher treatment resistance, and greater risk of adverse effects, pointing to unique, understudied mechanisms. The inflammatory hypothesis of depression and the “inflammaging” theory together suggest that chronic peripheral and central inflammation drive LLD pathogenesis. This systematic review and meta-analysis synthesized data from 18 observational studies (1,593 LLD patients, 2,776 healthy controls) to evaluate peripheral levels of interleukin-1β (IL-1β), IL-6, C-reactive protein (CRP), and tumor necrosis factor-α (TNF-α). All four markers were significantly elevated in LLD (Hedges’ g = 0.52-0.80, all p < 0.01), with high between-study heterogeneity (I2 = 83-90%). Sensitivity analyses restricting to studies with adequate confounding adjustment attenuated effect sizes, particularly for CRP (57% reduction) and TNF-α (36% reduction), but all markers remained significant. Subgroup analyses identified study population, geographic region, medication status, and sample size as potential effect moderators, but these should be interpreted as study-level moderators rather than evidence for patient-level subtypes. These findings are consistent with an inflammatory contribution to LLD, though the cross-sectional design precludes causal inference and the magnitude of effect may be partially inflated by incomplete control of somatic comorbidities. Future studies should employ individual participant data meta-analyses with multi-marker profiling to test whether distinct inflammatory subtypes exist.
Why this matters
[human-observational] Pooled findings from 18 observational studies extend the clinical correlates of inflammaging to late-life depression through elevated peripheral inflammatory biomarkers. These associations do not distinguish inflammation as a cause, consequence, or shared correlate of depression and do not establish that targeting these markers improves mood or alters human aging.